

Karoline Lerang

Date of birth: 12.07.1972

Contact details: Karoline Lerang
 Department of Rheumatology
 Oslo University Hospital- NORWAY
 Postboks 4959 Nydalen
 0424 Oslo

Current position(s):

From year	Position	% employment	Name of institution
2022-	Chief physician and senior researcher	50/50%	Department of Rheumatology, Oslo University Hospital, Norway

Previous positions:

Year		Position held	Name of institution
From	To		
2018	2022	Chief physician and Post doc 50/50%	Department of Rheumatology, Oslo University Hospital, Norway
2017	2018	Post doc	Department of Rheumatology, Oslo University Hospital, Norway
2015	2016	Chief physician	Department of Rheumatology, Oslo University Hospital, Norway
04.2015	08.2015	Assistant physician	Section for Pediatric Rheumatology, Oslo University Hospital, Norway
2013	2015	Assistant physician (rotation),	Department of Rheumatology, Diakonhjemmet Hospital, Norway
2011	2013	Assistant physician	Department of Rheumatology, Oslo University Hospital, Norway
2006	2006	Assistant physician	Department of Rheumatology, Oslo University Hospital, Norway
2003	2005	Assistant physician	Devision of Medicine, Oslo University Hospital, Norway
2002	2003	Assistant physician	Devision om Medicine, Stavanger University Hospital, Norway
2000	2002	Internship	Haugesund Hospital, Norway

Education:

Year	Academic degree	Name of institution
2015	Ph.D (dr. med)	University of Oslo (UiO)
2015	Specialist in Rheumatology	Norwegian medical association
2000	Cand med	University of Bergen (UiB)

Career breaks: Mother to two children born in 2005 and 2007

Relevant teaching:

Year	Teaching activity	Name of Institution
2012–15	Member of the teaching committee for assistant physicians in Rheumatology	Oslo University Hospital
2015–	Developed, managing and teaching at courses for SLE and Sjogrens patients	*Laering og mestringssenteret*, Rikshospital, OUH
2020–	Member of National guidelines for SLE	Norwegian society for rheumatology
2024–	Book chapter on SLE	Book; "Revmatologi"

Main supervisor of PhD students:

Year	Name of PhD student	Title of the thesis
2019–	Hilde Haukeland	Exploring Systemic Lupus Erythematosus in a Population-Based cohort: Trends of incidence, performance of classification criteria, and risk of malignancy
2020–2024	Sigrid Reppe Moe	Outcome and identification of early risk factors in a population based Systemic Lupus Erythematosus cohort set in Norway

Co-supervisor of PhD students

2024–	Mahdi Emdadi	Revolutionizing lupus nephritis diagnosis: A multi-center Scandinavian study
-------	--------------	--

PI role in local research projects

2023–		Biomarker Development for Early Diagnosis of Lupus Nephritis Using Liquid Biopsy
-------	--	--

Patent

2025–		A priority patent application covering the use of a biomarker as diagnostic test for Lupus Nephritis has been filed
-------	--	---

Fellowships

2017– Clinical post-doc stipend from the DAM foundation IF O 147 069 "Hvor farlig er SLE egentlig?" , grants from «Norsk revmatikerforening» (NRF), Vivi Irene Hansens fond til forskning av sykdommen lupus erythematosus disseminatus, «Fondsstiftelsen», Ragna og Egil Eikens legat til fremme av revmatismeforskningen

Other relevant assignments:

Mid-term evaluation committee

Year	Name of PhD student	
------	---------------------	--

2019	Håvard Fredtheim	Department of rheumatology, Oslo University Hospital
2021	Ingrid Egeland Christensen	Department of rheumatology, Oslo University Hospital

Examiner

Year	Name of master student	
2025	Tea M B Samuelsen	University of Oslo, medical faculty

Leadership

2017- Leder of SLE research group, department for Rheumatology, Oslo University Hospital
 2017- Leader of SLE network, South-Eastern Norway Regional Health Authority
 2025- SLEuro executive committee member

Invited reviewer

Reviewer for peer-reviewed journals such as Lupus, Lupus science and medicine, Scandinavian Journal of Rheumatology, Clinical Epidemiology, Journal of Women's Health, Arthritis care and Res.

Role in clinical trials

2025- Sub PI in Study CYTB323J12201 with title of "A Phase 2, adaptive, randomized, open-label, assessorblinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)
 2020–2023 PI in Study CAIN457Q12301 with tile of "A two year phase III randomized, double-blind, parallelgroup, placebo-controlled trial to evaluate the safety and efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination with SoC therapy, in patients with lupus nephritis".
 2015–2020 PI in Study 201842 with tile of "A randomized, double blind (sponsor open), comparative, multi-center study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab co-administration in subjects with primary Sjögren's syndrome".
 2004–2005 LUNDBECK study 10413 with tittle of "A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms"

Publications:

1. Lorentsen JLL, Brunborg C, Aasebø AT, Valeur J, Haavardsholm EA, Molberg Ø, Palm Ø, **Lerang K**. Rheumatology (Oxford). 2025 Aug 1;64(8):4703-4712. Incidence and prevalence of Behçet's disease in Oslo, Norway: a two-decade population-based analysis.
2. Moe SR, Haukeland H, Brunborg C, Botea A, Damjanic N, Wivestad GÅ, Øvreås HK, Bøe TB, Orre A, Torhild G, Provan SA, Molberg Ø, **Lerang K**. RMD Open. 2025 Sep 2;11(3):e005795. Accrual of thromboembolic events and antiphospholipid syndrome in new-onset systemic lupus erythematosus: a population-based inception cohort study.

3. Satrin A, Piga M, Gatto M, Fuentes-Silva Y, Puerta JAG, Padjen I, Pons-Estel G, Ugarte-Gil MF, Toro-Gutiérrez CE, Legge A, Duarte-Garcia A, Chasset F, Parodis I, Baumgaertner K, Chiche L, Monticelo OA, Oyoo O, Faria R, Izuka S, Silva-Ribeiro S, Togizbayev G, Opris-Belinski D, El Kibbi L, Aggarwal A, Maheswaranathan M, Lee TJ, Achieng S, Shumilova A, Cervera R, Chehab G, Parlindungan F, Van Leuven S, **Lerang K**, Andersen J, Marchiori F, Karakikla-Mitsakou Z, Sordet C, Arnaud L; international SLAKE development group. *Rheumatology (Oxford)*. 2025 Dec. International development and validation of a multilingual bank of items for the self-assessment of essential knowledge by systemic lupus erythematosus patients: the SLE Knowledge Assessment score (SLAKE).
4. Reid S, Sandling JK, Pucholt P, Sayadi A, Frodlund M, **Lerang K**, Gunnarsson I, Jönsen A, Syvänen AC, Molberg Ø, Rantapää-Dahlqvist S, Rudin A, Sjöwall C, Svenungsson E, Bengtsson AA, Rönblom L, Leonard D.J *Intern Med*. 2026 Jan;299(1):95-108.. Genetic risk factors and clinical manifestations of systemic lupus erythematosus: Large-scale analysis of genetic predisposition and disease subtypes.
5. Haukeland H, Moe SR, Brunborg C, Botea A, Damjanic N, Wivestad GÅ, Øvreås HK, Bøe TB, Orre A, Torhild G, Sanner H, **Lerang K**, Molberg Ø. Sensitivity of classification criteria from time of diagnosis in an incident systemic lupus erythematosus cohort: a population-based study from Norway. *RMD Open*. 2024 Aug 19;10(3)
6. Bolla E, Semb AG, Kerola AM, Ikdahl E, Petri M, Pons-Estel GJ, Karpouzas GA, Sfrikakis PP, Quintana R, Misra DP, Borba EF, Garcia-de la Torre I, Popkova TV, Artim-Esen B, Trolborg A, Fragoso-Loyo H, Ajeganova S, Yazici A, Aroca-Martinez G, Direskeneli H, Ugarte-Gil MF, Mosca M, Goyal M, Svenungsson E, Macieira C, Hoi A, **Lerang K**, Costedoat-Chalumeau N, Tincani A, Mirakhimov E, Acosta Colman I, Danza A, Massardo L, Blagojevic J, Yilmaz N, Tegzová D, Yavuz S, Korkmaz C, Hachulla E, Moreno Alvarez MJ, Muñoz-Louis R, Pantazis N, Tektonidou MG; SURF-SLE and APS collaborators. Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries. *Lancet Rheumatol*. 2024 Jul;6(7):e447-e459.
7. Haukeland H, R Moe S, Brunborg C, Botea A, Damjanic N, Wivestad GÅ, Øvreås H, Bøe T, Orre A, Garen T, Molberg Ø, **Lerang K**. Declining incidence of systemic lupus erythematosus in Norway 1999-2017: - Data from a population cohort identified by ICD-10 code and verified by classification. *Arthritis Rheumatol*. 2023 Dec
8. Hedenstedt A, Reid S, Sayadi A, Eloranta ML, Skoglund E, Bolin K, Frodlund M, **Lerang K**, Jönsen A, Rantapää-Dahlqvist S, Bengtsson AA, Rudin A, Molberg Ø, Sjöwall C, Sandling JK, Leonard D. B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus. *Lupus Sci Med*. 2023 Oct;10(2):e000926. doi: 10.1136/lupus-2023-000926
9. Moe SR, Haukeland H, Brunborg C, Botea A, Damjanic N, Wivestad GÅ, Øvreås H, Bøe T, Orre A, Garen T, Lilleby V, Provan SA, Molberg Ø, **Lerang K**. Persisting mortality gap in systemic lupus erythematosus; a population-based study on juvenile- and adult-onset SLE in Norway 1999-2022. *Rheumatology (Oxford)*. 2023 Sep 28:kead519. doi: 10.1093/rheumatology/kead519. Online ahead of print.
10. Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, Gardner DH, Henderson RB, Herdman M, **Lerang K**, Mistry P, Punwaney R, Seror R, Stone J, van Daele P, van Maurik A, Wisniacki N, Roth DA, Tak PP. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome. *JCI Insight*. 2022 Dec 8;7(23):e163030. doi: 10.1172/jci.insight.163030.
11. Piga M, Chessa E, Morand EF, Ugarte-Gil MF, Tektonidou M, van Vollenhoven R, Petri M, Arnaud L; PISCOS Investigator Group. Physician Global Assessment International

- Standardisation CONsensus in Systemic Lupus Erythematosus: the PISCOS study. *Lancet Rheumatol.* 2022 Jun;4(6):e441-e449.. Epub 2022 May 4
12. Reppe Moe S, Haukeland H, Molberg Ø, **Lerang K.** Long-Term Outcome in Systemic Lupus Erythematosus; Knowledge from Population-Based Cohorts. *J Clin Med.* 2021 Sep 22;10(19):4306. doi: 10.3390/jcm10194306.
 13. Reid, S., Hagberg, N., Sandling, J.K., Alexsson, A., Pucholt, P., Sjöwall, C., **Lerang, K.**, Jönsen, A., Gunnarsson, I., Syvänen, A.-C., Trolldborg, A.M., Voss, A., Bengtsson, A.A., Molberg, Ø., Jacobsen, S., Svenungsson, E., Rönnblom, L., Leonard, D., Interaction between the STAT4 rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus (2021) *Annals of the Rheumatic Diseases*, 80 (9), pp. 1183-1189. DOI: 10.1136/annrheumdis-2020-219727
 14. Bolin, K., Imgenberg-Kreuz, J., Leonard, D., Sandling, J.K., Alexsson, A., Pucholt, P., Haarhaus, M.L., Almlöf, J.C., Nititham, J., Jönsen, A., Sjöwall, C., Bengtsson, A.A., Rantapää-Dahlqvist, S., Svenungsson, E., Gunnarsson, I., Syvänen, A.-C., **Lerang, K.**, Trolldborg, A., Voss, A., Molberg, Ø., Jacobsen, S., Criswell, L., Rönnblom, L., Nordmark, G., Variants in BANK1 are associated with lupus nephritis of European ancestry (2021) *Genes and Immunity*, 22 (3), pp. 194-202. DOI: 10.1038/s41435-021-00142-8
 15. Sandling, J.K., Pucholt, P., Hultin Rosenberg, L., Farias, F.H.G., Kozyrev, S.V., Eloranta, M.-L., Alexsson, A., Bianchi, M., Padyukov, L., Bengtsson, C., Jonsson, R., Omdal, R., Lie, B.A., Massarenti, L., Steffensen, R., Jakobsen, M.A., Lillevang, S.Ø.T., **Lerang, K.**, Molberg, Ø., Voss, A., Trolldborg, A., Jacobsen, S., Syvänen, A.-C., Jönsen, A., Gunnarsson, I., Svenungsson, E., Rantapää-Dahlqvist, S., Bengtsson, A.A., Sjöwall, C., Leonard, D., Lindblad-Toh, K., Rönnblom, L., Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing (2021) *Annals of the Rheumatic Diseases*, 80 (1), pp. 109-117., DOI: 10.1136/annrheumdis-2020-218636
 16. Reppe Moe, S.E., Molberg, Ø., Strøm, E.H., **Lerang, K.**, Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort (2019) *Lupus*, 28 (7), pp. 818-825., DOI: 10.1177/0961203319847275
 17. Garen, T., **Lerang, K.**, Hoffmann-Vold, A.-M., Andersson, H., Midtvedt, Ø., Brunborg, C., Kilian, K., Gudbrandsson, B., Gunnarsson, R., Norby, G., Chaudhary, A., Thoen, J., Forseth, K.Ø., Fresjar, K., Førre, Ø., Haugen, M., Haga, H.-J., Gran, J.T., Gilboe, I.-M., Molberg, Ø., Palm, Ø., Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides (2019) *Rheumatology (United Kingdom)*, 58 (2), pp. 313-320., DOI: 10.1093/rheumatology/key285
 18. **Lerang, K.**, Gilboe, I.-M., Steinar Thelle, D., Gran, J.T., Mortality and years of potential life loss in systemic lupus erythematosus: A population-based cohort study (2014) *Lupus*, 23 (14), pp. 1546-1552., DOI: 10.1177/0961203314551083
 19. **Lerang, K.**, Gilboe, I., Garen, T., Thelle, D.S., Gran, J.T., High incidence and prevalence of systemic lupus erythematosus in Norway (2012) *Lupus*, 21 (12), pp. 1362-1369., DOI: 10.1177/0961203312458168
 20. **Lerang, K.**, Gilboe, I., Gran, J.T., Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus (2012) *Rheumatology*, 51 (4), art. no. ker318, pp. 663-669., DOI: 10.1093/rheumatology/ker318
 21. Norby, G.E., **Lerang, K.**, Holdaas, H., Gran, J.T., Strøm, E.H., Draganov, B., Os, I., Hartmann, A., Gilboe, I.-M., Lupusnefritt - diagnostikk og behandling (2010) *Tidsskrift for den Norske Lægeforening*, 130 (11), pp. 1140-1144., DOI: 10.4045/tidsskr.09.0583

Motivation letter for Karoline Lerang, Norway

I am highly motivated to continue serving on the SLEuro Executive Committee for a second term.

I have greatly valued my first year on the committee and remain strongly committed to strengthening European collaboration in education and research, as well as international cooperation in SLE.

I am particularly interested in working towards hosting an Advanced Workshop on SLE in Oslo and in developing Oslo as a future SLEuro Center for the SLEuro Mentorship Programme.

I would be honored to continue for another two-year term

Kind regards

Karoline Lerang
Senior consultant PhD
Department of Rheumatology
Oslo University Hospital
NORWAY